Insider Buying: GeneDx (NASDAQ:WGS) Director Buys 150,000 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc bought 150,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were bought at an average price of $56.44 per share, with a total value of $8,466,000.00. Following the completion of the transaction, the director directly owned 3,657,164 shares in the company, valued at approximately $206,410,336.16. This trade represents a 4.28% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Casdin Capital, Llc also recently made the following trade(s):

• On Friday, June 5th, Casdin Capital, Llc bought 50,000 shares of GeneDx stock. The stock was purchased at an average price of $52.86 per share, for a total transaction of $2,643,000.00.
• On Wednesday, May 20th, Casdin Capital, Llc acquired 140,000 shares of GeneDx stock. The shares were acquired at an average cost of $43.81 per share, for a total transaction of $6,133,400.00.
• On Tuesday, May 19th, Casdin Capital, Llc acquired 185,000 shares of GeneDx stock. The shares were acquired at an average cost of $42.60 per share, for a total transaction of $7,881,000.00.
• On Monday, May 18th, Casdin Capital, Llc bought 175,000 shares of GeneDx stock. The shares were bought at an average price of $42.55 per share, for a total transaction of $7,446,250.00.

GeneDx Stock Down 0.8%

WGS traded down $0.41 during trading on Monday, hitting $51.80. The company had a trading volume of 790,359 shares, compared to its average volume of 1,036,153. The company has a market capitalization of $1.54 billion, a PE ratio of -19.33 and a beta of 1.96. The firm’s 50-day moving average price is $55.44 and its 200 day moving average price is $92.65. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same quarter in the previous year, the business posted ($0.23) earnings per share. As a group, equities analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on WGS shares. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Jefferies Financial Group set a $150.00 target price on GeneDx in a research note on Monday, February 23rd. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Craig Hallum restated a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Institutional Trading of GeneDx

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in shares of GeneDx by 77.5% during the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock worth $15,066,000 after purchasing an additional 102,456 shares during the period. California State Teachers Retirement System boosted its stake in shares of GeneDx by 31.2% in the first quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after buying an additional 5,951 shares during the period. Ashford Capital Management Inc. grew its position in GeneDx by 31.9% during the first quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock worth $11,207,000 after buying an additional 42,186 shares in the last quarter. Quantinno Capital Management LP grew its position in GeneDx by 99.2% during the first quarter. Quantinno Capital Management LP now owns 3,810 shares of the company’s stock worth $245,000 after buying an additional 1,897 shares in the last quarter. Finally, First Light Asset Management LLC acquired a new stake in GeneDx during the first quarter worth approximately $15,601,000. Institutional investors own 61.72% of the company’s stock.

Key Stories Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
• Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
• Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
• Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
• Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.